Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone
Celldex Therapeutics shares fell about 4% to $29.58 in premarket trading Thursday, after surging 24% the previous session. The company completed enrollment in two global Phase 3 barzolvolimab studies for chronic spontaneous urticaria six months ahead of schedule. Topline data are expected in Q4 2026, with a U.S. BLA filing planned for 2027. Celldex ended 2025 with $518.6 million in cash and posted a full-year net loss of $258.8 million.
